Peer-reviewed veterinary case report
Maltese dog with adrenal cancer and spread treated successfully
By Park, Sin-Wook et al.·Published in Frontiers in veterinary science·2023·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Case report: Successful medical management of adrenocortical carcinoma with metastasis in a Maltese dog.
- Species:
- dog
Plain-English summary
A 12-year-old neutered male Maltese was diagnosed with an adrenal tumor and a liver mass after showing signs of illness. Tests confirmed he had a type of cancer called adrenocortical carcinoma (ACC) that had spread, making surgery too risky. The vet started him on a medication called trilostane, which helped improve his symptoms and lower his cortisol levels. Remarkably, after a year of treatment, follow-up scans showed that both the adrenal tumor and liver mass had shrunk significantly, indicating a positive response to the medication.
People also search for: Maltese dog adrenal tumor treatment · trilostane for dog cancer · dog liver mass symptoms
Abstract
INTRODUCTION: Adrenocortical carcinoma (ACC) with metastasis has a grave prognosis, and adrenalectomy is associated with a high perioperative mortality rate in dogs. A favorable outcome following trilostane treatment in patients with metastatic ACC confirmed by a decreased size of the adrenal tumor and metastatic lesions has not been reported in dogs. CASE DESCRIPTION: A 12-year-old neutered male Maltese dog was diagnosed with a right adrenal tumor and a hepatic mass. Adrenal-dependent hyperadrenocorticism (ADH) was diagnosed based on clinical signs and an adrenocorticotropic hormone stimulation test (ACTHST). In addition, tests for plasma metanephrine and normetanephrine ruled out a pheochromocytoma. Based on cytology and computed tomography, unresectable metastatic ACC was confirmed. The dog was managed with trilostane due to the presence of distant metastasis. Medical management improved the clinical signs and post-ACTHST cortisol concentrations. One year after the first presentation, the clinical signs and ACTHST test showed a favorable outcome. In addition, computed tomography revealed a decreased size of the right adrenal tumor and resolution of the hepatic mass. CONCLUSIONS: Trilostane could be considered as a treatment option for unresectable metastatic ACC. A decrease in tumor size following treatment with trilostane has not been reported in dogs. This case report is the first to demonstrate a favorable outcome of metastatic ACC following trilostane mono therapy for >1 year.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37519993/